• STAT+: With its Alzheimer's drug in turmoil, Biogen eyes a list of potential acquisitions

    8 days ago - By STAT

    Biogen, desperate to reverse the turmoil surrounding its controversial Alzheimer's treatment Aduhelm, has a shopping list of potential acquisitions, STAT has learned. And the company's risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive.
    The company, whose stock price is down nearly 50% since Aduhelm's June approval, is working with Goldman Sachs to find potential buyout targets, according to a person familiar with the companies' relationships who would share internal discussions only on the condition of anonymity. Continue to STAT+ to read the...
    Read more ...

     

  • With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer's treatment

    8 days ago - By STAT

    WASHINGTON - Medicare's proposal to restrict access to a controversial Alzheimer's drug has quickly reignited a long-simmering debate over how best to address the long-standing, systemic inequities in Alzheimer's care experienced by Black and Hispanic patients.
    Medicare on Tuesday put forth a draft plan to only cover Aduhelm for patients enrolled in a randomized clinical trial. Biogen, the company behind the drug, and major Alzheimer's patient groups all panned the proposal, saying it would make it harder for vulnerable populations to access the medicine. The Alzheimer's Association called...
    Read more ...